Back

Select your region

Corporate

Europe:

Flag Albania Albania Flag Bosnia and Herzegovina Bosnia and Herzegovina Flag Bulgaria Bulgaria Flag Croatia Croatia Flag Cyprus Cyprus Flag Montenegro Montenegro Flag Czech Republic Czech Republic Flag Denmark Denmark Flag Estonia Estonia Flag Spain Spain Flag Kosovo Kosovo Flag Lithuania Lithuania Flag Latvia Latvia Flag Luxembourg Luxembourg Flag Macedonia Macedonia Flag Germany Germany Flag Poland Poland Flag Portugal Portugal Flag Romania Romania Flag Serbia Serbia Flag Slovakia Slovakia Flag Slovenia Slovenia Flag Switzerland Switzerland Flag Sweden Sweden Flag Turkey Turkey Flag Hungary Hungary Flag United Kingdom United Kingdom Flag Italy Italy

Asia:

Flag UAE UAE Flag Hong Kong Hong Kong Flag Kuwait Kuwait Flag Lebanon Lebanon

Africa:

Flag South Africa South Africa

Arrange a consultation about stem cells

Learn more

Get in touch with us today!

Would you like to find out more about our services? Fill out the form below and we will contact you as soon as possible to provide you with all the necessary information and answer your questions.

    We would like to point out that the personal data provided in the form will be processed by FamiCord Suisse, based in Switzerland (BusinessPark Zug Sumpfstrasse 26, 6302 Zug), for the purpose of contacting you by telephone in connection with the provision of service information.

    Image

    List of life saving
    transplantations

    List of uses for stem cells approved by the FamiCord Group’s laboratories:

    Image
    List of uses for stem cells approved by the FamiCord Group’s laboratories:
    Nr. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
    1201 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Australia 71
    1202 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 76
    1203 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Canada 66
    1204 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 74
    1205 Apheresis Allogeneic Morbus Hodgkin Hematology 2025 Standard Therapy Germany 21
    1206 Apheresis Allogeneic Myelodysplastic Disorders Hematology 2025 Standard Therapy France 66
    1207 Apheresis Allogeneic Mielodysplastic Syndrome Hematology 2025 Standard Therapy USA 65
    1208 Apheresis Allogeneic T Lymphoblastic Lymphoma Hematology 2025 Standard Therapy Portugal 25
    1209 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Romania 29
    1210 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 37
    1211 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 49
    1212 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 32
    1213 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
    1214 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 43
    1215 Apheresis Allogeneic Hodking lymphoma Hematology 2025 Standard Therapy Serbia 32
    1216 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 66
    1217 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
    1218 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
    1219 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 68
    1220 Apheresis Allogeneic OMDS/ Myeloproliferative Neoplasie Hematology 2025 Standard Therapy Switzerland 46
    1221 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 3
    1222 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 75
    1223 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 58
    1224 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Greece 63
    1225 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
    1226 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 65
    1227 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Spain 49
    1228 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 30
    1229 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 66
    1230 Apheresis Allogeneic Chronic Lymphocyte Leukemia Hematology 2025 Standard Therapy Canada 55
    1231 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2025 Standard Therapy USA 64
    1232 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 16
    1233 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 73
    1234 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Ukraine 47
    1235 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 64
    1236 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 67
    1237 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 65
    1238 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 58
    1239 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Germany 57
    1240 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy RUSSIAN FEDERATION 22
    1241 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 33
    1242 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Slovakia 41
    1243 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Greece 54
    1244 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Ukraine 46
    1245 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Argentina 26
    1246 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 70
    1247 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 59
    1248 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 34
    1249 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Norway 53
    1250 Apheresis Allogeneic Other Immune System Hematology 2025 Standard Therapy USA 19
    1251 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Poland 6
    1252 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 68
    1253 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 72
    1254 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Germany 64
    1255 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy United Kingdom 33
    1256 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Italy 63
    1257 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 33
    1258 Apheresis Autologous Central Nervous System Lymphoma Hematology 2025 Standard Therapy Germany 61
    1259 Apheresis Allogeneic Acute lymphocytic leukemia Hematology 2025 Standard Therapy Germany 51
    1260 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 64
    1261 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 54
    1262 Apheresis Autologous Testicular tumor Hematology 2025 Standard Therapy Germany 42
    1263 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
    1264 Apheresis Autologous T-cell lymphoma Hematology 2025 Standard Therapy Germany 49
    1265 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 73
    1266 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 62
    1267 Apheresis Autologous Lymphoma Hodgkin Hematology 2025 Standard Therapy Portugal 39
    1268 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 60
    1269 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 70
    1270 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 64
    1271 Apheresis Autologous T-Cell Lymphoma Hematology 2025 Standard Therapy Germany 60
    1272 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 62
    1273 Apheresis Autologous Mantle Cell Lymphoma Hematology 2025 Standard Therapy Germany 60
    1274 Apheresis Autologous Multiple Myeloma Hematology 2025 Standard Therapy Germany 43
    1275 Apheresis Allogeneic Myeofibrosis Hematology 2025 Standard Therapy Poland 37
    1276 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Russia 22
    1277 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy NETHERLANDS 66
    1278 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 57
    1279 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 56
    1280 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 78
    1281 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 65
    1282 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 53
    1283 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Portugal 41
    1284 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy United Kingdom 56
    1285 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 22
    1286 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 36
    1287 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Canada 65
    1288 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
    1289 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Sweden 73
    1290 Apheresis Allogeneic NK LGL Leukemia Hematology 2025 Standard Therapy USA 42
    1291 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 29
    1292 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 71
    1293 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 68
    1294 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Czechia 64
    1295 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 10
    1296 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Brazil 57
    1297 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 21
    1298 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Lithuania 54
    1299 Apheresis Allogeneic Richter Transformation From CLL Hematology 2025 Standard Therapy Poland 55
    1300 Apheresis Allogeneic Richter Transformation From CLL Hematology 2025 Standard Therapy Poland 63